Corlentor

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
12-10-2021
Productkenmerken Productkenmerken (SPC)
12-10-2021

Werkstoffen:

ivabradine hydrochloride

Beschikbaar vanaf:

Les Laboratoires Servier

ATC-code:

C01EB17

INN (Algemene Internationale Benaming):

ivabradine

Therapeutische categorie:

CARDIAC THERAPY

Therapeutisch gebied:

Angina Pectoris; Heart Failure

therapeutische indicaties:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Product samenvatting:

Revision: 26

Autorisatie-status:

Authorised

Autorisatie datum:

2005-10-25

Bijsluiter

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CORLENTOR 5 MG FILM-COATED TABLETS
CORLENTOR 7.5 MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Corlentor is and what it is used for
2.
What you need to know before you take Corlentor
3.
How to take Corlentor
4.
Possible side effects
5
How to store Corlentor
6.
Contents of the pack and other information
1.
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute.
It is used in adult patients who do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most common s
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Corlentor 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Corlentor 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Corlentor 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Corlentor 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated :
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
Treatment of chronic heart failure
3
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the decision to ini
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 12-10-2021
Productkenmerken Productkenmerken Bulgaars 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 25-02-2019
Bijsluiter Bijsluiter Spaans 12-10-2021
Productkenmerken Productkenmerken Spaans 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 25-02-2019
Bijsluiter Bijsluiter Tsjechisch 12-10-2021
Productkenmerken Productkenmerken Tsjechisch 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 25-02-2019
Bijsluiter Bijsluiter Deens 12-10-2021
Productkenmerken Productkenmerken Deens 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 25-02-2019
Bijsluiter Bijsluiter Duits 12-10-2021
Productkenmerken Productkenmerken Duits 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 25-02-2019
Bijsluiter Bijsluiter Estlands 12-10-2021
Productkenmerken Productkenmerken Estlands 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 25-02-2019
Bijsluiter Bijsluiter Grieks 12-10-2021
Productkenmerken Productkenmerken Grieks 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 25-02-2019
Bijsluiter Bijsluiter Frans 12-10-2021
Productkenmerken Productkenmerken Frans 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 25-02-2019
Bijsluiter Bijsluiter Italiaans 12-10-2021
Productkenmerken Productkenmerken Italiaans 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 25-02-2019
Bijsluiter Bijsluiter Letlands 12-10-2021
Productkenmerken Productkenmerken Letlands 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 25-02-2019
Bijsluiter Bijsluiter Litouws 12-10-2021
Productkenmerken Productkenmerken Litouws 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 25-02-2019
Bijsluiter Bijsluiter Hongaars 12-10-2021
Productkenmerken Productkenmerken Hongaars 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 25-02-2019
Bijsluiter Bijsluiter Maltees 12-10-2021
Productkenmerken Productkenmerken Maltees 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 25-02-2019
Bijsluiter Bijsluiter Nederlands 12-10-2021
Productkenmerken Productkenmerken Nederlands 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 25-02-2019
Bijsluiter Bijsluiter Pools 12-10-2021
Productkenmerken Productkenmerken Pools 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 25-02-2019
Bijsluiter Bijsluiter Portugees 12-10-2021
Productkenmerken Productkenmerken Portugees 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 25-02-2019
Bijsluiter Bijsluiter Roemeens 12-10-2021
Productkenmerken Productkenmerken Roemeens 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 25-02-2019
Bijsluiter Bijsluiter Slowaaks 12-10-2021
Productkenmerken Productkenmerken Slowaaks 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 25-02-2019
Bijsluiter Bijsluiter Sloveens 12-10-2021
Productkenmerken Productkenmerken Sloveens 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 25-02-2019
Bijsluiter Bijsluiter Fins 12-10-2021
Productkenmerken Productkenmerken Fins 12-10-2021
Bijsluiter Bijsluiter Zweeds 12-10-2021
Productkenmerken Productkenmerken Zweeds 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 25-02-2019
Bijsluiter Bijsluiter Noors 12-10-2021
Productkenmerken Productkenmerken Noors 12-10-2021
Bijsluiter Bijsluiter IJslands 12-10-2021
Productkenmerken Productkenmerken IJslands 12-10-2021
Bijsluiter Bijsluiter Kroatisch 12-10-2021
Productkenmerken Productkenmerken Kroatisch 12-10-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Kroatisch 25-02-2019

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten